Research Article

You have full text access to this OnlineOpen article

Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trial

  1. Maureen D. Mayes1,*,
  2. Daniel O'Donnell2,
  3. Naomi F. Rothfield3,
  4. M. E. Csuka4

Article first published online: 5 FEB 2004

DOI: 10.1002/art.20036

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 50, Issue 2, pages 553–557, February 2004

Additional Information

How to Cite

Mayes, M. D., O'Donnell, D., Rothfield, N. F. and Csuka, M. E. (2004), Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trial. Arthritis & Rheumatism, 50: 553–557. doi: 10.1002/art.20036

Author Information

  1. 1

    University of Texas–Houston Health Science Center

  2. 2

    Wayne State University School of Medicine, Detroit, Michigan

  3. 3

    University of Connecticut, Farmington

  4. 4

    Medical College of Wisconsin, Milwaukee

*Division of Rheumatology and Clinical Immunogenetics, University of Texas–Houston Health Science Center, 6431 Fannin Street, MSB 5.270, Houston, TX 77030

Publication History

  1. Issue published online: 5 FEB 2004
  2. Article first published online: 5 FEB 2004
  3. Manuscript Accepted: 21 OCT 2003
  4. Manuscript Received: 14 JAN 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (61K)

REFERENCES

  • 1
    Le CH, Morales A, Trentham DEK. Minocycline in early diffuse scleroderma [letter]. Lancet 1998; 352: 1755–6.
  • 2
    Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al, the UK Scleroderma Study Group. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992; 31: 457–60.
  • 3
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194–203.
    Direct Link:
  • 4
    Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 871–9.
  • 5
    Erikson MS, Unemori EN. Relaxin clinical trials in systemic sclerosis. In: TregearGW, IvellR, BathgateRA, WadeJD, editors. Relaxin 2000: Proceedings of the World Congress on Relaxin 2000. Dordrecht (The Netherlands): Kluwer Academic Publishers; 2001. p. 373–81.
  • 6
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 7
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 8
    Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996; 22: 861–78.
  • 9
    Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al, the UK Scleroderma Study Group. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992; 31: 457–60.
  • 10
    Medsger TA Jr, Steen VD, Ziegler G, Rodnan GP. The natural history of skin involvement in progressive systemic sclerosis [abstract]. Arthritis Rheum 1980; 23: 720–1.
View Full Article (HTML) Get PDF (61K)